dyslipidemia

(redirected from Dyslipidemias)
Also found in: Dictionary.

dyslipidemia

 [dis-lip″id-e´me-ah]
abnormality in, or abnormal amounts of, lipids and lipoproteins in the blood; see hyperlipidemia and hypolipidemia.

dyslipidemia

/dys·lip·id·e·mia/ (-lip″id-e´me-ah) abnormality in, or abnormal amounts of, lipids and lipoproteins in the blood.

dyslipidemia

(dĭs-lĭp′ĭ-dē′mē-ə)
n.
An abnormal concentration of lipids or lipoproteins in the blood.

dys·lip′i·de′mic (-mĭk) adj.

dyslipidemia

[dislip′id·ē′mē·ə]
Etymology: Gk, dys, difficult + lipid + Gk, haima, blood
abnormality in, or abnormal amounts of, lipids and lipoproteins in the blood. See also hyperlipidemia, hypolipoproteinemia.

dyslipidemia

Metabolic disease Any defect in lipoprotein metabolism–eg ↑ cholesterol, ↑ TGs, combined hyperlipidemia, and ↓ HDL-C; dyslipidemias may be 1º–ie nosologies a sui generis or 2º to other medical conditions–eg, DM or hypothyroidism

dys·lip·i·de·mi·a

(dis-lip'i-dē'mē-ă)
Any biochemical disorder characterized by one or more abnormal levels of blood lipids.
References in periodicals archive ?
Studies have shown that patients living with HIV infection have increased cardiovascular disease risk factors, including dyslipidemia and glucose abnormalities.
Guidelines 4 and 5, on treatment of dyslipidemias in adults and adolescents, call for lifestyle changes (such as improving diet, increasing physical activity, and reducing weight).
com/research/x64jlc/treatment_algorith) has announced the addition of the "Treatment Algorithms: Dyslipidemia - Statin Monotherapies Dominate the Market but Uncontrolled Lipid Levels Remain an Issue" report to their offering.
This message will set the tone for new National Kidney Foundation guidelines for managing dyslipidemias.
MBX-8025 is an oral drug candidate that is being evaluated for the treatment of dyslipidemia.
The market for treating dyslipidemias continues to grow rapidly, with the fenofibrate segment of the market demonstrating average annual growth of 30% over the last three years.
Dyslipidemias include elevated LDL (bad) cholesterol, low HDL (good) cholesterol and/or elevated triglycerides, all of which increase the risk of cardiovascular disease, the leading cause of death in the United States.
LY929, for the treatment of type 2 diabetes, metabolic diseases and dyslipidemias, entered clinical development in mid-2002.
We are very pleased that GSK has decided to continue development of 501516, which may represent an important advance in the treatment of dyslipidemias and associated cardiovascular disorders," said Andres Negro-Vilar, M.
Potential to Treat Diabetes, Metabolic Diseases and Dyslipidemias
We have developed a broad platform of molecules with distinct receptor specificity and tissue selectivity, allowing us to bring to the clinic molecules with enhanced activity and broader therapeutic profiles for the treatment of type II diabetes, dyslipidemias and associated cardiovascular disorders.